Masimo Co. (NASDAQ:MASI) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 7.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,163 shares of the medical equipment provider's stock after selling 2,000 shares during the period. New York State Common Retirement Fund's holdings in Masimo were worth $3,994,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Blue Trust Inc. boosted its stake in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares during the period. CIBC Asset Management Inc boosted its stake in shares of Masimo by 5.6% during the fourth quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider's stock valued at $270,000 after purchasing an additional 87 shares during the period. MML Investors Services LLC increased its stake in Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock worth $274,000 after buying an additional 96 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Masimo by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 12,300 shares of the medical equipment provider's stock valued at $2,033,000 after acquiring an additional 100 shares in the last quarter. Finally, UMB Bank n.a. increased its holdings in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 123 shares during the period. 85.96% of the stock is owned by institutional investors.

Remove Ads

Masimo Stock Down 3.3 %

Shares of NASDAQ:MASI traded down $6.26 on Tuesday, hitting $184.37. 364,829 shares of the company's stock were exchanged, compared to its average volume of 621,640. The company has a market capitalization of $9.95 billion, a PE ratio of 127.26 and a beta of 1.02. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm's 50-day moving average is $174.13 and its 200 day moving average is $154.63.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Sell-side analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MASI. Wells Fargo & Company increased their target price on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Piper Sandler upped their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Stifel Nicolaus restated a "buy" rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.